https://www.yiliao.com/index.php?action=history&feed=atom&title=M6620
M6620 - 版本历史
2026-04-19T02:42:57Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=M6620&diff=316003&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-28T08:02:38Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>M6620</strong>（通用名：Berzosertib，原研发代号：VX-970）是由德国默克（Merck KGaA）开发的一款强效、高选择性、<strong>静脉注射型</strong>（IV）<strong>[[ATR激酶]]</strong>抑制剂。作为全球首个进入临床阶段的 ATR 抑制剂，M6620 完成了该靶点的“概念验证”（Proof of Concept），证实了阻断 ATR-CHK1 通路可显著增强化疗药物（如吉西他滨、顺铂）的抗肿瘤活性，特别是在 <strong>[[ATM]] 缺失</strong>或高复制压力的肿瘤中。尽管 M6620 展现了积极的疗效，但由于静脉给药的局限性，默克目前的研发重心已转向其第二代<strong>口服</strong> ATR 抑制剂 <strong>[[Tuvusertib]] (M1774)</strong>。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">M6620</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Berzosertib / VX-970 (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:IV_drug_administration_concept.jpg|100px|静脉给药：M6620的主要特征]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">状态：一代 ATRi (静脉)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">通用名</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[Berzosertib]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发企业</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[Merck KGaA]] (引进自Vertex)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">靶点</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">ATR Kinase</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">剂型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>静脉输注 (IV)</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">继任者</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">[[Tuvusertib]] (M1774)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">关键试验</th><br />
<td style="padding: 6px 12px; color: #0f172a;">NCI 卵巢癌 II 期</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">从 M6620 到 M1774：默克的 ATR 接力</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
M6620 是 ATR 抑制剂领域的“开路先锋”，但其药学特性限制了其商业化潜力。默克（Merck KGaA）的策略调整反映了该类药物的进化方向：<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">特征</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">第一代：M6620 (Berzosertib)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">第二代：M1774 (Tuvusertib)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">给药途径</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>静脉 (IV)</strong><br>患者需住院或门诊输液，依从性低。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #16a34a; font-weight: bold;">口服 (Oral)<br>居家服用，适合长期维持治疗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">药代动力学</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">半衰期短，体内浓度波动大。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">生物利用度高，稳态浓度维持更好。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">战略定位</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">化疗增敏（联合 Gem/Cis）。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">合成致死（单药）及新型联合（PARPi/IO）。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">M6620 的临床遗产</h2><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">定义了“高复制压力”人群</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
M6620 的临床试验首次证实了：<strong>无 PARP 抑制剂治疗史</strong>（即 PARP-naïve）的卵巢癌患者，对 ATR 抑制剂更敏感。这是因为这类肿瘤往往保留了高水平的复制压力（Replication Stress），是 ATR 抑制剂的最佳攻击目标。<br />
</p><br />
</div><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>卵巢癌：</strong> 联合吉西他滨显著改善了铂耐药患者的 PFS (HR 0.57)。</li><br />
<li style="margin-bottom: 12px;"><strong>小细胞肺癌 (SCLC)：</strong> 联合拓扑替康在铂难治患者中观察到了 30% 的缓解率，验证了 SCLC (TP53/RB1 缺失) 对 ATR 抑制的易感性。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Konstantinopoulos PA, et al. (2020).</strong> <em>Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer.</em> <strong>[[The Lancet Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：确立了 M6620 历史地位的研究，证明了 ATR 抑制剂在临床上确实有效，鼓舞了后续口服药物的开发。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Thomas, A. et al. (2018).</strong> <em>Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：探索了与拓扑异构酶抑制剂的联合，特别是在小细胞肺癌中展示了令人鼓舞的持久缓解。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Merck KGaA. (2021).</strong> <em>Strategic Update on DNA Damage Response (DDR) Portfolio.</em> <strong>[[Pipeline Report]]</strong>. <br><br />
<span style="color: #475569;">[点评]：默克内部管线调整报告，标志着资源从 M6620 正式向 M1774 (Tuvusertib) 倾斜。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
M6620 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">前身代号</td><br />
<td style="padding: 10px 15px; color: #334155;">[[VX-970]] (Vertex)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">家族接力</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Tuvusertib]] (M1774, 二代) • [[Peposertib]] (DNA-PK)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心机制</td><br />
<td style="padding: 10px 15px; color: #334155;">[[化疗增敏]] • [[合成致死]] • [[复制叉崩塌]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">适应症</td><br />
<td style="padding: 10px 15px; color: #334155;">[[卵巢癌]] • [[小细胞肺癌]] • [[神经内分泌瘤]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020